80 FR 68547 - Prospective Grant of Exclusive License: Development of Therapeutics To Treat Brain Injury and Neurodegenerative Disease
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health Federal Register Volume 80, Issue 214 (November 5, 2015)
National Institutes of Health
Federal Register Volume 80, Issue 214 (November 5, 2015)
| Page Range | 68547-68547 | |
| FR Document | 2015-28245 |
[Federal Register Volume 80, Number 214 (Thursday, November 5, 2015)] [Notices] [Page 68547] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2015-28245] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: Development of Therapeutics To Treat Brain Injury and Neurodegenerative Disease AGENCY: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Public Health Service, DHHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7, that the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to Astrocyte Pharmaceuticals, Inc., (``Astrocyte''), a company incorporated under the laws of Delaware and having an office in Cambridge, Massachusetts, to practice the following inventions embodied in the following patent applications: US Provisional Patent Appl. No. 60/176,373 entitled, ``Methanocarba cycloalkyl nucleoside analogues,'' filed 14 Jan 2000 [HHS reference E-176-1999/0-US-01]; Intl. Appl. No. PCT/US01/00981, entitled, ``Methanocarba cycloalkyl nucleoside analogues,'' filed 12 Jan 2001 [HHS reference E-176-1999/0-PCT-02]; Australia Patent No. 2001230913, issued 13 Oct 2005 [HHS reference E- 176-1999/0-AU-03]; Canada Patent No. 2.397,366, issued 15 Mar 2011 [HHS reference E-176-1999/0-CA-04]; European Patent Appl. No. 01903043.6 entitled, filed 12 Jan 2001 [HHS Ref No E-176-1999/0-EP-05]; US Patent No. 7,087,589, issued 8 Aug 2006 [HHS reference E-176-1999/0-US-06]; US patent No. 7,790,735, issued 8 Aug 2006 [HHS reference E-176-1999/0-US- 07]; and Great Britain patent No. 1252160, issued 16 Aug 2006 [HHS reference E-176-1999/0-US-08]. The patent rights in these inventions have been assigned to the United States of America. The territories included in this license may be worldwide. The field of use may be related to ``Use of the patent rights in the development and sale of therapeutics for cerebral trauma, stroke, and neurodegenerative disorders.'' DATES: Only written comments or applications for a license (or both) which are received by the Technology Advancement Office of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) on or before November 20, 2015 will be considered. ADDRESSES: Requests for copies of the patent application, patents, inquiries, comments, and other materials relating to the contemplated exclusive license should be directed to: Patrick McCue, Ph.D., Senior Licensing and Patenting Manager, Technology Advancement Office, The National Institute of Diabetes and Digestive and Kidney Diseases, 12A South Drive, Bethesda, MD 20892, Telephone: (301) 435-5560; Email: patrick.mccue@nih.gov. A signed confidentiality non-disclosure agreement will be required to receive copies of any patent applications that have not been published by the United States Patent and Trademark Office or the World Intellectual Property Organization. SUPPLEMENTARY INFORMATION: The technology provides novel nucleoside and nucleotide derivatives that are agonist or antagonists of P1 and P2 receptors and may be useful in the treatment or prevention of various diseases including airway diseases, cancer, cardiac arrhythmias, cardiac ischemia, epilepsy, and Huntington's Disease. The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the NIDDK receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404. Properly filed competing applications for a license received by the NIDDK in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: October 30, 2015. Anna Z. Amar, Acting Deputy Director, Technology Advancement Office, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. [FR Doc. 2015-28245 Filed 11-4-15; 8:45 am] BILLING CODE 4140-01-P
![Federal Register / Vol. 80, No. 214 / Thursday, November 5, 2015 / Notices 68547
III. Electronic Access SUMMARY: This notice, in accordance States Patent and Trademark Office or
Persons with access to the Internet with 35 U.S.C. 209(c)(1) and 37 CFR the World Intellectual Property
may obtain the document at either part 404.7, that the National Institute of Organization.
http://www.fda.gov/ScienceResearch/ Diabetes and Digestive and Kidney
SUPPLEMENTARY INFORMATION:
SpecialTopics/RunningClinicalTrials/ Diseases, National Institutes of Health,
Department of Health and Human The technology provides novel
ProposedRegulationsand nucleoside and nucleotide derivatives
DraftGuidances/default.htm, or http:// Services, is contemplating the grant of
an exclusive patent license to Astrocyte that are agonist or antagonists of P1 and
www.hhs.gov/ohrp/newsroom/ P2 receptors and may be useful in the
index.html, or http:// Pharmaceuticals, Inc., (‘‘Astrocyte’’), a
company incorporated under the laws of treatment or prevention of various
www.regulations.gov. diseases including airway diseases,
Delaware and having an office in
Dated: October 23, 2015. Cambridge, Massachusetts, to practice cancer, cardiac arrhythmias, cardiac
Karen B. DeSalvo, the following inventions embodied in ischemia, epilepsy, and Huntington’s
Acting Assistant Secretary for Health. U.S. the following patent applications: US Disease.
Department of Health and Human Services. Provisional Patent Appl. No. 60/176,373 The prospective exclusive license will
Dated: October 27, 2015. entitled, ‘‘Methanocarba cycloalkyl be royalty bearing and will comply with
Leslie Kux, nucleoside analogues,’’ filed 14 Jan 2000 the terms and conditions of 35 U.S.C.
Assistant Commissioner for Policy, U.S. Food [HHS reference E–176–1999/0–US–01]; 209 and 37 CFR part 404. The
and Drug Administration. Intl. Appl. No. PCT/US01/00981, prospective exclusive license may be
[FR Doc. 2015–27986 Filed 11–4–15; 8:45 am] entitled, ‘‘Methanocarba cycloalkyl granted unless within fifteen (15) days
nucleoside analogues,’’ filed 12 Jan 2001 from the date of this published notice,
BILLING CODE 4164–01–P
[HHS reference E–176–1999/0–PCT–02]; the NIDDK receives written evidence
Australia Patent No. 2001230913, issued and argument that establishes that the
DEPARTMENT OF HEALTH AND 13 Oct 2005 [HHS reference E–176– grant of the license would not be
HUMAN SERVICES 1999/0–AU–03]; Canada Patent No. consistent with the requirements of 35
2.397,366, issued 15 Mar 2011 [HHS U.S.C. 209 and 37 CFR part 404.
National Institutes of Health reference E–176–1999/0–CA–04]; Properly filed competing applications
European Patent Appl. No. 01903043.6 for a license received by the NIDDK in
National Institute on Aging; Amended entitled, filed 12 Jan 2001 [HHS Ref No response to this notice will be treated as
Notice of Meeting E–176–1999/0–EP–05]; US Patent No. objections to the contemplated license.
Notice is hereby given of a change in 7,087,589, issued 8 Aug 2006 [HHS Comments and objections submitted in
the meeting of the National Institute on reference E–176–1999/0–US–06]; US response to this notice will not be made
Aging Special Emphasis Panel, patent No. 7,790,735, issued 8 Aug 2006 available for public inspection and, to
November 12, 2015, 10:00 a.m. to [HHS reference E–176–1999/0–US–07]; the extent permitted by law, will not be
November 12, 2015, 02:00 p.m., and Great Britain patent No. 1252160, released under the Freedom of
National Institute on Aging, Gateway issued 16 Aug 2006 [HHS reference E– Information Act, 5 U.S.C. 552.
Building, 7201 Wisconsin Avenue, Suite 176–1999/0–US–08]. The patent rights Dated: October 30, 2015.
2C212, Bethesda, MD, 20892 which was in these inventions have been assigned Anna Z. Amar,
published in the Federal Register on to the United States of America. The Acting Deputy Director, Technology
October 19, 2015, 80 FR 63236. territories included in this license may Advancement Office, National Institute of
The meeting notice is amended to be worldwide. The field of use may be Diabetes and Digestive and Kidney Diseases,
change the date of the meeting from related to ‘‘Use of the patent rights in National Institutes of Health.
November 12, 2015 to November 24, the development and sale of [FR Doc. 2015–28245 Filed 11–4–15; 8:45 am]
2015. The meeting is closed to the therapeutics for cerebral trauma, stroke, BILLING CODE 4140–01–P
public. and neurodegenerative disorders.’’
Dated: October 30, 2015. DATES: Only written comments or
applications for a license (or both) DEPARTMENT OF HEALTH AND
Melanie J. Gray,
which are received by the Technology HUMAN SERVICES
Program Analyst, Office of Federal Advisory
Committee Policy. Advancement Office of the National
Institute of Diabetes and Digestive and National Institutes of Health
[FR Doc. 2015–28230 Filed 11–4–15; 8:45 am]
Kidney Diseases (NIDDK) on or before National Cancer Institute; Notice of
BILLING CODE 4140–01–P
November 20, 2015 will be considered. Closed Meetings
ADDRESSES: Requests for copies of the
DEPARTMENT OF HEALTH AND patent application, patents, inquiries, Pursuant to section 10(d) of the
HUMAN SERVICES comments, and other materials relating Federal Advisory Committee Act, as
to the contemplated exclusive license amended (5 U.S.C. App.), notice is
National Institutes of Health should be directed to: Patrick McCue, hereby given of the following meetings.
Ph.D., Senior Licensing and Patenting The meetings will be closed to the
Prospective Grant of Exclusive Manager, Technology Advancement public in accordance with the
License: Development of Therapeutics Office, The National Institute of provisions set forth in sections
To Treat Brain Injury and Diabetes and Digestive and Kidney 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
jstallworth on DSK7TPTVN1PROD with NOTICES
Neurodegenerative Disease Diseases, 12A South Drive, Bethesda, as amended. The grant applications and
AGENCY: National Institute of Diabetes MD 20892, Telephone: (301) 435–5560; the discussions could disclose
and Digestive and Kidney Diseases, Email: patrick.mccue@nih.gov. A signed confidential trade secrets or commercial
National Institutes of Health, Public confidentiality non-disclosure property such as patentable material,
Health Service, DHHS. agreement will be required to receive and personal information concerning
copies of any patent applications that individuals associated with the grant
ACTION: Notice.
have not been published by the United applications, the disclosure of which
VerDate Sep<11>2014 15:06 Nov 04, 2015 Jkt 238001 PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 E:\FR\FM\05NON1.SGM 05NON1](https://thefederalregister.org/doc/80_FR_68761/page/1.svg)
Document Created: 2015-12-14 15:02:39
Document Modified: 2015-12-14 15:02:39
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice. | |
| Dates | Only written comments or applications for a license (or both) which are received by the Technology Advancement Office of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) on or before November 20, 2015 will be considered. | |
| FR Citation | 80 FR 68547 |
2024 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR